InnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in China
The first patient was dosed in clinical trial of ICP-B381 for solid tumors. No bispecific ADC targeting PSMA and STEAP1 was approved for marketing globally